Abstract
Plasmodium falciparum parasites resistant to the combination sulfadoxine-pyrimethamine are spreading in Africa, particularly in East Africa. This is a matter of concern because there are no other affordable drugs available. This article provides the evidence indicating that sulfadoxine-pyrimethamine resistance can be reversed in vitro and discusses how this information might be exploited to extend the therapeutic lifetime of sulfadoxine-pyrimethamine in vivo.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antimalarials / pharmacology*
-
Antimalarials / therapeutic use
-
Drug Combinations
-
Drug Resistance / drug effects
-
Drug Synergism
-
Drug Therapy, Combination
-
Folic Acid / drug effects
-
Folic Acid / metabolism
-
Folic Acid Antagonists / pharmacology*
-
Folic Acid Antagonists / therapeutic use
-
Malaria, Falciparum / drug therapy
-
Plasmodium falciparum / drug effects*
-
Plasmodium falciparum / metabolism
-
Probenecid / pharmacology*
-
Probenecid / therapeutic use
-
Pyrimethamine / pharmacology*
-
Pyrimethamine / therapeutic use
-
Sulfadoxine / pharmacology*
-
Sulfadoxine / therapeutic use
Substances
-
Antimalarials
-
Drug Combinations
-
Folic Acid Antagonists
-
fanasil, pyrimethamine drug combination
-
Sulfadoxine
-
Folic Acid
-
Probenecid
-
Pyrimethamine